Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5539_Библиотеки_им_академика_М_И_Перельмана.pdf
TABLE OF CONTENTS
List of Contributors ......................................................................................... xv
Preface .............................................................................................................. xxi
Introduction .............................................................................................. 1
• Targeted Analyses ................................................................................1
• Restriction Fragment LengthPolymorphism (RFLP) ................................. 2
• Unknown Mutation Detections ............................................................ 3
• Conclusions ........................................................................................ 11
• References ..........................................................................................12
Chapter 1 Advances In Molecular Diagnostics ........................................................17
Chapter 2 Tumor Genomic Profiling Reports From Different Vendors: A
Comparison With Respect To Clinical Action Ability of
The Provided Data ..................................................................................21
• Abstract ..............................................................................................21
• Introduction ........................................................................................ 22
• Materials and Methods ........................................................................24
• Results ................................................................................................27
• Discussion ..........................................................................................39
• Conclusions ........................................................................................ 43
• References ..........................................................................................45
Chapter 3 Clinical Next-Generation Sequencing For Somatic Mutation
Detection- Advancements And Commercialization Strategies ................51
• Abstract ..............................................................................................51
• Background ........................................................................................52
• Sequencing Methods ...........................................................................54
• Bioinformatics And Analysis Software .................................................59
• Development And
Commercialization Strategies .............................................................62
• Challenges .......................................................................................... 67
• Conclusion .........................................................................................68
• References ..........................................................................................69
Chapter 4 Molecular Diagnostics In Melanocytic Tumors: The Pathologists
Perspective .............................................................................................. 73
• Abstract ..............................................................................................73
• References ..........................................................................................77
Chapter 5 Recent Advances In Molecular Diagnostics And
Treatment Of Heart Muscle Diseases —From Biopsy-Focused
To Systemic Diagnostics .......................................................................... 79
• Abstract ..............................................................................................79
• Introduction ........................................................................................ 80
• Endomyocardial Biopsy ......................................................................81
• Histological Analysis ...........................................................................83
• Immunohistochemical Examination On Intramyocardial Inammation 83
• Molecular Virology For Detection Of Myocardial Infections ................ 85
• Indirect Immunouorescence Testing Of Autoimmunity ......................87
• Immunoassays ....................................................................................87
• Proling Technologies For Mirnas Or Gene Expression—
The Way To Organ-Specic and Systemic Diagnosis ........................... 89
• Proof Of Disease-Related Gene
Mutations For Cardiomyopathies ........................................................91
• Diagnostic-Based Treatment Decisions ................................................93
• Conclusions ........................................................................................ 95
• Acknowledgements .............................................................................96
• References ..........................................................................................96
Chapter 6 Molecular Diagnosis Of Brucellosis: A Brief Report ............................. 103
• Abstract ............................................................................................103
• Introduction ...................................................................................... 104
• Molecular Methods ........................................................................... 105
• Future Developments ........................................................................ 107
• Conclusions ...................................................................................... 107
• References ........................................................................................107
x
Chapter 7 Molecular Diagnostics For Precision Medicine In Colorectal
Cancer: Current Status And
Future Perspective .................................................................................113
• Abstract ............................................................................................113
• Introduction ...................................................................................... 114
• Current Guidelines For Targeted Therapy In Crc .................................115
• Roles Of Pathologists.........................................................................117
• Molecular Assays For Targeted Therapy ..............................................120
• Future Perspectives ...........................................................................123
• Conclusion .......................................................................................129
• References ........................................................................................131
Chapter 8 Clinical Significance of Molecular
Diagnostic Tools For Bacterial Bloodstream Infections: A
Systematic Review .................................................................................147
• Abstract ............................................................................................147
• Introduction ...................................................................................... 148
• Methods ............................................................................................149
• Results And Discussion ..................................................................... 150
• Conclusion .......................................................................................162
• References .......................................................................................163
Chapter 9 A Complete Molecular Diagnostic Procedure For Applications
In Surveillance And Subtyping of Avian Influenza Virus ....................... 169
• Abstract ............................................................................................169
• Introduction ...................................................................................... 170
• Material And Methods.......................................................................171
• Results ..............................................................................................175
• Discussion ........................................................................................178
• Acknowledgments ............................................................................181
• References ........................................................................................181
Chapter 10 Molecular Diagnostic Tests For Microsporidia ...................................... 185
• Abstract ............................................................................................185
• Introduction ...................................................................................... 186
• Nucleic Acid-Based Detection Methods ............................................188
• Antigen-Based Detection Methods .................................................... 199
xi
• Antibody-Based Detection Methods .................................................. 200
• Detection Of Microsporidia From Environmental Samples ................200
• Conclusion .......................................................................................202
• References ........................................................................................203
Chapter 11 Molecular Markers in The Diagnosis and Treatment Of Cancer ............215
• Acknowledgment .............................................................................. 217
• References ........................................................................................217
Chapter 12 RAC1B: A New Player in The Scenario of Thyroid Tumorigenesis? .......219
• Abstract ............................................................................................219
• Thyroid Malignancies ........................................................................220
• The Ras Superfamily Of Small Gtpases .............................................. 221
• The Hyper-Activatable Rac1
Splicing Variant, Rac1b .....................................................................223
• Rac1b Over Expression and Malignant Progression ........................... 226
• Conclusion .......................................................................................227
• References ........................................................................................228
Chapter 13 Cd38 As Surrogate Marker For Hiv Infection In
Antiretroviral Naive And Antiretroviral
Experienced Patients In Kenya ..............................................................233
• Abstract ............................................................................................233
• Introduction ...................................................................................... 234
• Materials And Methods ..................................................................... 236
• Data Analysis .................................................................................... 239
• Results ..............................................................................................239
• Discussion ........................................................................................242
• Conclusion .......................................................................................246
• Acknowledgement ............................................................................ 246
• References ........................................................................................247
Chapter 14 Cip2a As A Potential Stratification Marker And Target For
Tumor Responsiveness To Dna Damaging Therapies .............................251
• Abstract ............................................................................................251
• Introduction ...................................................................................... 252
• Potential Role For Cip2a And Stem Cell Marker Oct4 As Cancer
Patient Stratication Marker For DNA Damaging Therapies ...............253
xii
• References ........................................................................................256
Chapter 15 Ca125 As A Marker For The Follow-Up Of
Relapsing Polysierositis: A Case Report ................................................. 261
• Introduction ...................................................................................... 261
• Case Report ......................................................................................262
• References ........................................................................................264
Chapter 16 Molecular Docking To Test For Efficacy Of Porphyrin Compounds
To Cure Alzheimers Disease ..................................................................265
• Abstract ............................................................................................265
• Introduction ...................................................................................... 266
• Methodology ....................................................................................267
• Results And Discussion ..................................................................... 268
• Conclusion .......................................................................................270
• References ........................................................................................270
Citations ................................................................................................273
Index ..................................................................................................... 277
xiii
LIST OF CONTRIBUTORS
Tavan Janvilisri
Department of Biochemistry, Faculty of Science, Mahidol University, Bangkok 10400,
Thailand
Arun K. Bhunia
Department of Food Science and Department of Comparative Pathobiology, Purdue
University, West Lafayette, IN 47907, USA
Joy Scaria
Department of Population Medicine and Diagnostic Sciences, College of Veterinary
Medicine, Cornell University, Ithaca, NY 14850, USA
Yuriko Mori
CHI Institute for Research and Innovation, Center for Translational Research, Baltimore,
USA
Victor Levenson
CHI Institute for Research and Innovation, Center for Translational Research, Baltimore,
USA
Jeffrey Otto
CHI Institute for Research and Innovation, Center for Translational Research, Baltimore,
USA
Andrew Hesse
Transgenomic, Inc, 5 Science Park, New Haven, CT, USA 06477.
Christopher Chen
Transgenomic, Inc, 5 Science Park, New Haven, CT, USA 06477.
Honey V. Reddi
Transgenomic, Inc, 5 Science Park, New Haven, CT, USA 06477.
Gerardo Ferrara
Department of Oncology, Anatomic Pathology Unit, Geatano Rummo General Hospital,
Benevento, Italy
Giuseppina Improta
Laboratory of Clinical Research and Advanced Diagnostics, IRCCS-CROB Centro di
Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy
Dirk Lassner
Institute of Cardiac Diagnostics and Therapy, Berlin, Germany
Christine Sabine Siegismund
Institute of Cardiac Diagnostics and Therapy, Berlin, Germany
Jenny Stehr
Institute of Cardiac Diagnostics and Therapy, Berlin, Germany
Maria Rohde
Institute of Cardiac Diagnostics and Therapy, Berlin, Germany
Felicitas Escher
Institute of Cardiac Diagnostics and Therapy, Berlin, Germany
Department of Cardiology and Pneumonology, Charité-Universityhospital Berlin,
Campus Benjamin Franklin, Berlin, Germany.
Carsten Tschöpe
Department of Cardiology and Pneumonology, Charité-Universityhospital Berlin,
Campus Benjamin Franklin, Berlin, Germany.
Ulrich Michael Gross
Institute of Cardiac Diagnostics and Therapy, Berlin, Germany
Uwe Kühl
Institute of Cardiac Diagnostics and Therapy, Berlin, Germany
Department of Cardiology and Pneumonology, Charité-Universityhospital Berlin,
Campus Benjamin Franklin, Berlin, Germany.
Heinz-Peter Schultheiss
Department of Cardiology and Pneumonology, Charité-Universityhospital Berlin,
Campus Benjamin Franklin, Berlin, Germany.
Panagiotis Andriopoulos
Department of Nursing, University of Peloponnese, Valioti and Plataion, Sparta, Greece
Maria Tsironi
Department of Nursing, University of Peloponnese, Valioti and Plataion, Sparta, Greece
xvi
Guoli Chen
Department of Pathology, Penn State College of Medicine, Milton S. Hershey Medical
Center, Hershey, PA, USA
Zhaohai Yang
Department of Pathology, Penn State College of Medicine, Milton S. Hershey Medical
Center, Hershey, PA, USA
James R. Eshleman
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore,
MD, USA
George J. Netto
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore,
MD, USA
Ming-Tseh Lin
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore,
MD, USA
Jean Pierre Rutanga
School of Science, College of Science and Technology, University of Rwanda, BP 56,
Huye, Rwanda
Therese Nyirahabimana
School of Science, College of Science and Technology, University of Rwanda, BP 56,
Huye, Rwanda
Chun-Hsien Tseng
Animal Health Research Institute, Danshui, Taipei 25158, Taiwan
Hsiang-Jung Tsai
Animal Health Research Institute, Danshui, Taipei 25158, Taiwan
Graduate Institute of Veterinary Medicine, College of Bioresource and Agriculture,
National Taiwan University, No. 1, Section 4, Roosevelt Road, Taipei 106, Taiwan
Chung-Ming Chang
Research Center for Emerging Viral Infections, Department of Medical Biotechnology
and Laboratory Science, College of Medicine, Chang Gung University, Kwei-Shan,
Taoyuan 333, Taiwan
Kaya Ghosh
Department of Pathology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
Department of Biological Sciences, Rutgers University, Newark, NY 07102, USA
xvii
Louis M. Weiss
Department of Pathology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
Department of Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USA
Murat Gokden
Department of Pathology, University of Arkansas for Medical Sciences, Little Rock,
AR 72205, USA
Aurelio Ariza
Department of Pathology, Autonomous University of Barcelona, 08916 Barcelona,
Spain
Konstantinos Arnaoutakis
Hematology-Oncology Division, Department of Internal Medicine, University of
Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Ana Luisa Silva
Research Unit of Molecular Pathobiology, Portugal
Márcia Faria
Research Unit of Molecular Pathobiology, Portugal
Liliana Capinha
Research Unit of Molecular Pathobiology, Portugal
Maria João Bugalho
Research Unit of Molecular Pathobiology, Portugal
Endocrinology service, Portuguese Oncology Institute of Lisbon Francisco Gentil E. P.
E, Lisbon, Portugal
University Clinic of Endocrinology, NOVA Medical School / Faculty of Medical
Sciences, New University of Lisbon, Portugal
Njuguna AN
Institute of Tropical Medicine and Infectious Diseases, Jomo Kenyatta University of
Agriculture and Technology, Nairobi, Kenya
Juma KK
Department of Biochemistry and Biotechnology, Kenyatta University, Nairobi, Kenya
Waihenya RK
Department of Zoology, Jomo Kenyatta University of Agriculture and Technology,
Nairobi, Kenya